Pasar al contenido principal

ENTORNO LIPIDICO Y PROGRESION DE LA ENFERMEDAD HEPATICA: UN PAPEL METABOLICO PARA EL FACTOR DE TRANSCRIPCION E2F2

RTI2018-095134-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DEL PAIS VASCO EUSKAL HERRIKO UNIBERTSITATEA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids

  • Ruiz de Gauna, Mikel
  • Biancaniello, Francesca
  • González-Romero, Francisco
  • Rodrigues, Pedro M.
  • Lapitz, Ainhoa
  • Gómez-Santos, Beatriz
  • Olaizola, Paula
  • Di Matteo, Sabina
  • Aurrekoetxea, Igor
  • Labiano, Ibone
  • Nieva, Ane
  • Benito-Vicente, Asier
  • Perrugorria, María J.
  • Apodaka, Maider
  • Paiva, Nuno A.
  • Sáenz de Urturi, Diego
  • Buqué, Xabier
  • Delgado, Igotz
  • Martín, César
  • Azkargorta, Mikel
  • Elortza, Félix
  • Calvisi, Diego F.
  • Andersen, Jesper B.
  • Álvaro, Domenico
  • Cardinale, Vincenzo
  • Bujanda, Luis
  • Banales, Jesús M.
  • Aspichueta, Patricia
[Background and Aims] Cholangiocarcinoma (CCA) includes a heterogeneous group of biliary cancers with a dismal prognosis. We investigated if lipid metabolism is disrupted in CCA and its role in tumor proliferation., [Approach and Results] The in vitro and in vivo tumorigenic capacity of five human CCA cell lines was analyzed. Proteome, lipid content, and metabolic fluxes were evaluated in CCA cells and compared with normal human cholangiocytes (NHC). The Akt1/NOTCH1 intracellular cytoplasmic domain (Nicd1)-driven CCA mouse model was also evaluated. The proteome of CCA cells was enriched in pathways involved in lipid and lipoprotein metabolism. The EGI1 CCA cell line presented the highest tumorigenic capacity. Metabolic studies in high (EGI1) versus low (HUCCT1) proliferative CCA cells in vitro showed that both EGI1 and HUCCT1 incorporated more fatty acids (FA) than NHC, leading to increased triglyceride storage, also observed in Akt1/Nicd1-driven CCA mouse model. The highly proliferative EGI1 CCA cells showed greater uptake of very-low-density and HDLs than NHC and HUCCT1 CCA cells and increased cholesteryl ester content. The FA oxidation (FAO) and related proteome enrichment were specifically up-regulated in EGI1, and consequently, pharmacological blockade of FAO induced more pronounced inhibition of their tumorigenic capacity compared with HUCCT1. The expression of acyl-CoA dehydrogenase ACADM, the first enzyme involved in FAO, was increased in human CCA tissues and correlated with the proliferation marker PCNA., [Conclusions] Highly proliferative human CCA cells rely on lipid and lipoprotein uptake to fuel FA catabolism, suggesting that inhibition of FAO and/or lipid uptake could represent a therapeutic strategy for this CCA subclass., This work was supported by “Ayudas para apoyar grupos de investigación del sistema Universitario Vasco” (IT971‐16 to PA), MCIU/AEI/FEDER, UE (2018‐095134‐B‐100 to PA and by the University of Basque Country COLAB20/01 to PA; Spanish Carlos III Health Institute (ISCIII) (FIS PI15/01132, PI18/01075, PI21/00922, and Miguel Servet Program CON14/00129 and CPII19/00008 to JMB; FIS PI14/00399, PI17/00022 and PI20/00186 to MJP; Sara Borrell [CD19/00254 to PMR]) cofinanced by “Fondo Europeo de Desarrollo Regional” (FEDER); CIBERehd (ISCIII) to JMB, MJP, PMR, PA and LB); “Diputación Foral Gipuzkoa” (DFG15/010, DFG16/004 to JMB and 2020‐CIEN‐000067‐01 to PMR), Department of Health of the Basque Country (2019111024 to MJP, 2017111010 to JMB, and 2020111077 to JMB and PA), “Euskadi RIS3” (2016222001, 2017222014, 2018222029, 2019222054, 2020333010 to JMB), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD to JMB) and Department of Industry of the Basque Country (Elkartek: KK‐2020/00008 to JMB); La Caixa Scientific Foundation (HR17‐00601 to JMB). “Fundación Científica de la Asociación Española Contra el Cáncer” (AECC Scientific Foundation, to JMB). AMMF‐The Cholangiocarcinoma Charity (EU/2019/AMMFt/001, to JMB and PMR). MRDG was funded by “Fundación Científica de la Asociación Española Contra el Cáncer” (AECC de Bizkaia), MJP was funded by the Spanish Ministry of Economy and Competitiveness (MINECO: “Ramón y Cajal” Program RYC‐2015‐17755), IL, AL and FG‐R by the Basque Government (PRE_2016_1_0152, PRE_2018_2_0195 and PRE 2020 2 02500, respectively), AN‐Z and BG‐S by the UPV/EHU, AB‐V by “Programa de especialización de Personal Investigador Doctor” at the UPV/EHU (2019‐2020) and MA by the MCIU/AEI/FEDER., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

  • Lima, Natália da Silva
  • Fondevila, Marcos F.
  • Nóvoa, Eva
  • Buqué, Xabier
  • Mercado-Gómez, María
  • Gallet, Sarah
  • González-Rellán, María Jesús
  • Fernández, Uxía
  • Loyens, Anne
  • García-Vence, María
  • Chantada-Vázquez, María del Pilar
  • Bravo, Susana Belén
  • Marañón, Patricia
  • Senra, Ana
  • Escudero, Adriana
  • Leiva, Magdalena
  • Guallar, Diana
  • Fidalgo, Miguel
  • Gomes, Pedro
  • Claret, Marc
  • Sabio, Guadalupe
  • Varela-Rey, Marta
  • Delgado, Teresa C.
  • Montero-Vallejo, Rocío
  • Ampuero, Javier
  • López, Miguel
  • Diéguez, Carlos
  • Herrero, Laura
  • Serra, Dolors
  • Schwaninger, Markus
  • Prevot, Vincent
  • Gallego-Durán, Rocío
  • Romero-Gómez, Manuel
  • Iruzubieta, Paula
  • Crespo, Javier
  • Martínez-Chantar, María Luz
  • García-Monzón, Carmelo
  • González-Rodríguez, Águeda
  • Aspichueta, Patricia
  • Nogueiras, Rubén
[Background & Aims] Autophagy-related gene 3 (ATG3) is an enzyme mainly known for its actions in the LC3 lipidation process, which is essential for autophagy. Whether ATG3 plays a role in lipid metabolism or contributes to non-alcoholic fatty liver disease (NAFLD) remains unknown., [Methods] By performing proteomic analysis on livers from mice with genetic manipulation of hepatic p63, a regulator of fatty acid metabolism, we identified ATG3 as a new target downstream of p63. ATG3 was evaluated in liver samples from patients with NAFLD. Further, genetic manipulation of ATG3 was performed in human hepatocyte cell lines, primary hepatocytes and in the livers of mice., [Results] ATG3 expression is induced in the liver of animal models and patients with NAFLD (both steatosis and non-alcoholic steatohepatitis) compared with those without liver disease. Moreover, genetic knockdown of ATG3 in mice and human hepatocytes ameliorates p63- and diet-induced steatosis, while its overexpression increases the lipid load in hepatocytes. The inhibition of hepatic ATG3 improves fatty acid metabolism by reducing c-Jun N-terminal protein kinase 1 (JNK1), which increases sirtuin 1 (SIRT1), carnitine palmitoyltransferase 1a (CPT1a), and mitochondrial function. Hepatic knockdown of SIRT1 and CPT1a blunts the effects of ATG3 on mitochondrial activity. Unexpectedly, these effects are independent of an autophagic action., [Conclusions] Collectively, these findings indicate that ATG3 is a novel protein implicated in the development of steatosis., This work has been supported by grants from FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación (PA: RTI2018-095134-B-100; DS and LH: SAF2017-83813-C3-1-R; MLMC: RTC2019-007125-1; CD: BFU2017-87721; ML: RTI2018–101840-B-I00; GS; PID2019-104399RB-I00; RN: RTI2018-099413-B-I00 and RED2018-102379-T; MLMC: SAF2017-87301-R; TCD: RTI2018-096759-A-100), FEDER/Instituto de Salud Carlos III (AGR: PI19/00123), Xunta de Galicia (ML: 2016-PG068; RN: 2015-CP080 and 2016-PG057), Fundación BBVA (RN, GS and MLM), Proyectos Investigación en Salud (MLMC: DTS20/00138), Sistema Universitario Vasco (PA: IT971-16); Fundación Atresmedia (ML and RN), Fundación La Caixa (M.L., R.N. and M.C.), Gilead Sciences International Research Scholars Program in Liver Disease (MVR), Marató TV3 Foundation (DS: 201627), Government of Catalonia (DS: 2017SGR278) and European Foundation for the Study of Diabetes (RN and GS). This research also received funding from the European Community’s H2020 Framework Programme (ERC Synergy Grant-2019-WATCH- 810331, to RN, VP and MS). Centro de Investigación Biomédica en Red (CIBER) de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd) and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem). CIBERobn, CIBERehd and CIBERdem are initiatives of the Instituto de Salud Carlos III (ISCIII) of Spain which is supported by FEDER funds. We thank MINECO for the Severo Ochoa Excellence Accreditation to CIC bioGUNE (SEV-2016-0644)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Liver osteopontin is required to prevent the progression of age-related nonalcoholic fatty liver disease

  • Gómez-Santos, Beatriz
  • Sáenz de Urturi, Diego
  • Núñez-García, Maitane
  • González-Romero, Francisco
  • Buqué, Xabier
  • Aurrekoetxea, Igor
  • Gutiérrez de Juan, Virginia
  • González-Rellán, María J.
  • García-Monzón, Carmelo
  • González-Rodríguez, Águeda
  • Mosteiro, Lorena
  • Errazti, Gaizka
  • Mifsut, Patricia
  • Gaztambide, Sonia
  • Castaño, Luis
  • Martín, César
  • Nogueiras, Rubén
  • Martínez-Chantar, María Luz
  • Syn, Wing-Kin
  • Aspichueta, Patricia
Osteopontin (OPN), a senescence-associated secretory phenotype factor, is increased in patients with nonalcoholic fatty liver disease (NAFLD). Cellular senescence has been associated with age-dependent hepatosteatosis. Thus, we investigated the role of OPN in the age-related hepatosteatosis. For this, human serum samples, animal models of aging, and cell lines in which senescence was induced were used. Metabolic fluxes, lipid, and protein concentration were determined. Among individuals with a normal liver, we observed a positive correlation between serum OPN levels and increasing age. This correlation with age, however, was absent in patients with NAFLD. In wild-type (WT) mice, serum and liver OPN were increased at 10 months old (m) along with liver p53 levels and remained elevated at 20m. Markers of liver senescence increased in association with synthesis and concentration of triglycerides (TG) in 10m OPN-deficient (KO) hepatocytes when compared to WT hepatocytes. These changes in senescence and lipid metabolism in 10m OPN-KO mice liver were associated with the decrease of 78 kDa glucose-regulated protein (GRP78), induction of ER stress, and the increase in fatty acid synthase and CD36 levels. OPN deficiency in senescent cells also diminished GRP78, the accumulation of intracellular TG, and the increase in CD36 levels. In 20m mice, OPN loss led to increased liver fibrosis. Finally, we showed that OPN expression in vitro and in vivo was regulated by p53. In conclusion, OPN deficiency leads to earlier cellular senescence, ER stress, and TG accumulation during aging. The p53-OPN axis is required to inhibit the onset of age-related hepatosteatosis., This work was supported by Ayudas para apoyar grupos de investigación del sistema Universitario Vasco (IT971-16 to P.A.), MINECO-FEDER (SAF2017-87301-R to M.L.M-Ch) MCIU/AEI/FEDER, UE (RTI2018-095134-B-100 to P.A. and RTI2018-099413-B-I00 to RN, Asociación Española contra el Cáncer, Canceres raros (M.L.M-Ch), La Caixa Foundation (to M.L.M-Ch), Ayudas Fundación BBVA a equipos de Investigación Científica 2018 (to M.L.M-Ch), Xunta de Galicia (RN: 2015-CP080 and 2016- PG057), Fundación BBVA (RN), and European Foundation for the Study of Diabetes (RN). ISCIII-FEDER PI17/00535 (to C.G-M.), ISCIII-FEDER CP14/00181 and PI16/00823 (to A.G- R.), and Francisco Cobos Foundation (to A.G-R.). CiC bioGUNE thanks MINECO for the Severo Ochoa Excellence Accreditation (SEV-2016- 0644)., Peer reviewed